Methylprednisolone Acetate Injectable Suspension USP — Class II drug recall D-0743-2021
Terminated recall by Teva Pharmaceuticals USA, reported 2021-08-25, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0743-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Parsippany, NJ, United States |
| Recall initiated | 2021-07-29 |
| Classified | 2021-08-16 |
| Reported by FDA | 2021-08-25 |
| Terminated | 2024-06-04 |
| Distributed | Nationwide (US) |
| Quantity | 50,713 vials |
| Reason classes | sterility |
| NDC | 00703-0051-01, 00703-0063-01 |
| Expiration dates | 2021-07, 2021-11, 2022-01, 2022-03 |
Product
Methylprednisolone Acetate Injectable Suspension USP, 80 mg/mL, packaged in a) 1 mL Single-Dose vials (0703-0051-01), and b) 5mL Multi Dose Vials (NDC 0703-0063-01), Rx only, TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454.
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0743-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.